----

| California                                                     |   | 27-1041563                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |

| Title of each class        |   | Name of exchange on which registered |
|----------------------------|--------|--------------------------------------|
| Common Stock, no par value |   | NYSE MKT                             |

----

----

| Large accelerated filer ☐                                             | Accelerated filer ☐         |
|-----------------------------------------------------------------------------|-----------------------------------|
| Non-accelerated filer ☒ (Do not check if a smaller reporting company) | Smaller reporting company ☐ |

----

|       |                  |                                                                                                                | PageNumber |
|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------|------------|
| Part I.    | Financial Information |                                                                                                                |
|       |                  |                                                                                                                |       |
|       | Item 1 -              | Business                                                                                                            | 5          |
|       |                  |                                                                                                                |       |
|       | Item 1A               | Risk Factors                                                                                                        | 33         |
|       |                  |                                                                                                                |       |
|       | Item 1B               | Unresolved Staff Comments                                                                                           | 49         |
|       |                  |                                                                                                                |       |
|       | Item 2 -              | Properties                                                                                                          | 49         |
|       |                  |                                                                                                                |       |
|       | Item 3 -              | Legal Proceedings                                                                                                   | 49         |
|       |                  |                                                                                                                |       |
|       | Item 4 -              | Mine Safety Disclosures                                                                                             | 49         |
|       |                       |                                                                                                                |       |
| Part II.   | Other Information     |                                                                                                                |
|       |                  |                                                                                                                |       |
|       | Item 5 -              | Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities | 50         |
|       |                  |                                                                                                                |       |
|       | Item 6 -              | Selected Financial Data                                                                                             | 51         |
|       |                  |                                                                                                                |       |
|       | Item 7 -              | Management’s Discussion and Analysis of Financial Condition and Results of Operations                         | 52         |
|       |                  |                                                                                                                |       |
|       | Item 7A -             | Quantitative and Qualitative Disclosures about Market Risk                                                          | 58         |
|       |                  |                                                                                                                |       |
|       | Item 8 -              | Financial Statements and Supplementary Data                                                                         | 61         |
|       |                  |                                                                                                                |       |
|       | Item 9 -              | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure                                | 83         |
|       |                  |                                                                                                                |       |
|       | Item 9A-              | Controls and Procedures                                                                                             | 83         |
|       |                  |                                                                                                                |       |
|       | Item 9B               | Other Information                                                                                                   | 84         |
|       |                  |                                                                                                                |       |
| Part III.  | Item 10 -             | Directors, Executive Officers, and Corporate Governance                                                             | 125        |
|       |                  |                                                                                                                |       |
|       | Item 11 -             | Executive Compensation                                                                                              | 125        |
|       |                  |                                                                                                                |       |
|       | Item 12 -             | Security Ownership of Certain Beneficial Owners and Management, and Related Stockholder Matters                     | 125        |
|       |                  |                                                                                                                |       |
|       | Item 13 -             | Certain Relationships and Related Transactions, and Director Independence                                           | 125        |
|       |                  |                                                                                                                |       |
|       | Item 14 -             | Principal Accounting Fees and Services                                                                              | 125        |
|       |                  |                                                                                                                |       |
| Part IV    | Item 15 -             | Exhibits, Financial Statement Schedules                                                                             | 85         |
|       |                  |                                                                                                                |       |
| Signatures | 87                    |

----

Table of Contents

----

Table of Contents

| Item 1. | Business |
|---------|----------|

|  | · | Improve health outcomes through early diagnoses and better prognostic capabilities; |
|--|--------|-------------------------------------------------------------------------------------|

|  | · | Reduce the cost of care through the avoidance of more costlier diagnostic procedures, including invasive biopsy and cystoscopic procedures; and |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Improve the quality of life for cancer patients by reducing the anxiety associated with non-definitive diagnoses. |
|--|--------|-------------------------------------------------------------------------------------------------------------------|

|  | · | Diagnostic tests to prioritize in our development program; |
|--|--------|------------------------------------------------------------|

|  | · | Diagnostic tests we should market ourselves; |
|--|--------|----------------------------------------------|

----

Table of Contents

|  | · | Diagnostic tests we should co-market through an alliance with one or more other companies; and |
|--|--------|------------------------------------------------------------------------------------------------|

|  | · | Diagnostic tests we should out-license to third parties for development and/or commercialization. |
|--|--------|---------------------------------------------------------------------------------------------------|

|  | · | Reduced disclosure about our executive compensation arrangements; |
|--|--------|-------------------------------------------------------------------|

|  | · | No non-binding shareholder advisory votes on executive compensation or golden parachute arrangements; and |
|--|--------|-----------------------------------------------------------------------------------------------------------|

|  | · | Exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting. |
|--|--------|------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | Confirmatory diagnostics – confirmatory diagnostics are used in conjunction with a current standard of care screening procedure. For example, our lung confirmatory diagnostic would be used in conjunction with LDCT to confirm a suspicious result by yielding a secondary suspicious versus benign result. In the case of the benign results, patients would not need additional invasive procedures to determine the presence of cancer. In the case of the suspicious results, additional procedures would be highly warranted; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Screening diagnostics – screening diagnostics would replace or be used as an alternative to existing screening procedures. A screener diagnostic for breast cancer could be used as an alternative to MRIs for women with a family history of breast cancer, BRCA mutations or dense breast tissue. This test could become part of a routine annual or other periodic physical examination; |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Recurrence diagnostics also known as prognostics – are used for patients who had previously been diagnosed with cancer but are currently in remission. In the case of our bladder diagnostic, the test could be used in lieu of a painful, costly cystoscopy to confirm whether the cancer has returned. This test could become part of the follow-up examination of bladder cancer patients; and |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Companion diagnostics – used by physicians to help determine an optimal therapy for a specific patient. An example of this would be HER2+ and Herceptin. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | Evaluated over 50 potential cancer biomarkers discovered by OncoCyte and BioTime using antibody-based ELISA technology in blood serum samples from a proprietary sample bank derived from over 600 donors, including patients with cancers of the breast, colon, and pancreas, as well as healthy volunteers; |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Presentation of preliminary findings at American Thoracic Society in May 2015 showing a ROC score of 0.88 for a lung confirmatory mRNA and miRNA classifier; |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Initiated a clinical study in 2015 collecting blood samples from patients undergoing LDCTs for the detection of lung cancer; |
|--|--------|------------------------------------------------------------------------------------------------------------------------------|

|  | · | Initiated a first and second clinical study collecting urine samples from patients undergoing cystoscopies to support development of confirmatory and recurrence diagnostics for bladder cancer; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Presented preliminary findings at American Association for Cancer Research in April 2015 showing a ROC score of 0.91 for our bladder cancer confirmatory and recurrence diagnostic; |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Developed a preliminary classifier diagnostic for breast cancer based on a number of mRNA biomarkers; and |
|--|--------|-----------------------------------------------------------------------------------------------------------|

|  | · | Filed several patent applications in the United States and worldwide with claims covering use of various cancer markers in the diagnosis and/or prognosis of various cancers. |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | · | Person who has smoked a pack a day (20 cigarettes) for 30 years; |
|--|--------|------------------------------------------------------------------|

|  | · | Person who has smoked 15 cigarettes a day for 40 years; and/or |
|--|--------|----------------------------------------------------------------|

|  | · | Person who has smoked 40 cigarettes a day for 15 years. |
|--|--------|---------------------------------------------------------|

----

Table of Contents

|  | · | 0.5 to 1% mortality and |
|--|--------|-------------------------|

|  | · | 4-20% major complications. |
|--|--------|----------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | · | Out-licensing or co-marketing partnership for our bladder cancer confirmatory and recurrence diagnostic; |
|--|--------|----------------------------------------------------------------------------------------------------------|

|  | · | Completion of a prospective patient study for analytical validation of our lung cancer diagnostic; |
|--|--------|----------------------------------------------------------------------------------------------------|

|  | · | Analytical validation of our lung and breast confirmatory diagnostics (analytical validation is a series of experiments with the same samples to ensure that the test results can be replicated under different circumstances); |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Launch of a confirmatory diagnostic test for lung cancer; |
|--|--------|-----------------------------------------------------------|

|  | · | Locked down assay concept for a screening diagnostic test for lung cancer; |
|--|--------|----------------------------------------------------------------------------|

|  | · | Completion of a prospective patient study for analytical validation of our breast cancer diagnostic; |
|--|--------|------------------------------------------------------------------------------------------------------|

|  | · | Analytical validation of our breast confirmatory diagnostics; |
|--|--------|--------------------------------------------------------------------|

|  | · | Proof of concept for a screening diagnostic or confirmatory diagnostic test for breast cancer; |
|--|--------|------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | Establish a CLIA laboratory and obtain a certificate of registration, a certificate of compliance and inspection for all 50 states. |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | · | The claims of any patents that are issued may not provide meaningful protection, may not provide a basis for commercially viable diagnostic tests or may not provide us with any competitive advantages; |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Our patents may be challenged by third parties; |
|--|--------|-------------------------------------------------|

|  | · | Others may have patents that relate to our technology or business that may prevent us from marketing our diagnostic test candidates unless we are able to obtain a license to those patents; |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Patent applications to which we have rights may not result in issued patents; and |
|--|--------|-----------------------------------------------------------------------------------|

|  | · | We may not be successful in developing additional proprietary technologies that are patentable. |
|--|--------|-------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | · | Third-party payers that provide coverage to the patient, such as an insurance company, a managed care organization or a governmental payer program; |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Physicians or other authorized parties, such as hospitals or independent laboratories, that order the testing service or otherwise refer the testing services to us; or |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Patients in cases where the patient has no insurance, has insurance that partially covers the testing, or owes a co-payment, co-insurance or deductible amount. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | Analysis of multiple biomarkers of DNA, RNA or proteins combined with a unique algorithm to yield a single patient-specific result; |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Cleared or approved by the FDA; or |
|--|--------|------------------------------------|

|  | · | Meets other similar criteria established by the Secretary of Health and Human Services. |
|--|--------|-----------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | If data shows that the list price was greater than 130% of the payment using established methodology, generally a weighted median, CMS will recoup the difference from the laboratory through a payment claw back. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Payment will be updated annually based on the weighted median of commercial payer reimbursement. |
|--|--------|--------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Item 1A. | Risk Factors |
|----------|--------------|

----

Table of Contents

|  | · | We are attempting to develop new medical diagnostic tests and technologies. The main focus of our business is on diagnostic tests for cancer. Our diagnostic tests are being developed through the use of blood and urine samples obtained in prospective and retrospective clinical trials involving humans, but none of our diagnostic tests have been used in medicine to diagnose cancer. Our technologies many not prove to be sufficiently efficacious to use in the diagnosis of cancer. |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Some of our research could also have applications in new cancer therapeutics. None of our experimental therapeutic technologies have been applied in human medicine and have only been used in laboratory studies in vitro. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The experimentation we are doing is costly, time consuming, and uncertain as to its results. We incurred research and development expenses amounting to approximately, $4.5 million, and $4.0 million during years ended December 31, 2015 and 2014, respectively. Since 2011, most of our research has been devoted to the development of our lead diagnostic tests to detect lung cancer, breast cancer, and bladder cancer. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | If we are successful in developing a new technology or diagnostic test, refinement of the new technology or diagnostic test and definition of the practical applications and limitations of the technology or diagnostic test may take years and require the expenditure of large sums of money. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | We need to successfully develop and market or license the diagnostic tests that we are developing in order to earn revenues in sufficient amounts to meet our operating expenses. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Without diagnostic test sales or licensing fee revenues, we will not be able to operate at a profit, and we will not be able to cover our operating expenses without raising additional capital. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Should we be able to successfully develop and market our diagnostic tests we may not be able to receive reimbursement for them from payers, such as health insurance companies, health maintenance organizations and Medicare, or any reimbursement that we receive may be lower than we anticipate. |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | Physicians and hospitals may be reluctant to try a new diagnostic test due to the high degree of risk associated with the application of new technologies and diagnostic test in the field of human medicine, especially if the new test differs from the current standard of care for detecting cancer in patients. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Competing tests for the initial diagnosis, reoccurrence diagnosis and optimal treatment of cancer are being manufactured and marketed by established companies and by other smaller biotechnology companies. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Currently there are two diagnostic tests for lung cancer and multiple diagnostic tests for bladder cancer on the market. There is one diagnostic product for breast cancer that has been approved in Europe. In order to compete with other diagnostic tests, particularly any that sell at lower prices, our diagnostic tests will have to provide medically significant advantages or be more cost effective. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | There also is a risk that our competitors may succeed in developing safer, more accurate or more cost effective diagnostic tests that could render our diagnostic tests and technologies obsolete or noncompetitive |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | We plan to continue to incur substantial research and development expenses and we anticipate that we will be incurring significant sales and marketing costs as we develop and commercialize our diagnostic test candidates. We will need to raise additional capital to pay operating expenses until we are able to generate sufficient revenues from diagnostic test sales, royalties, and license fees, and we will need to sell additional equity or debt securities to meet those capital needs. |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Our ability to raise additional equity or debt capital will depend not only on progress made in developing our diagnostic tests, but also will depend on access to capital and conditions in the capital markets. There is no assurance that we will be able to raise capital at times and in amounts needed to finance the development and commercialization of our diagnostic tests, establishment of a CLIA certified diagnostic laboratory, and general operations. Even if capital is available, it may not be available on terms that we or our shareholders would consider favorable. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Sales of additional equity securities by us could result in the dilution of the interests of our shareholders. |
|--|--------|----------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | · | The diagnostic tests that we may develop cannot be sold until the CMS or the FDA, and corresponding foreign regulatory authorities approve the laboratory tests or the IVDs for medical use. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | We will have to obtain a CLIA certificate of registration license for our laboratory for the manufacture and use of diagnostic tests and as part of the submission, our laboratory will be inspected. |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | In addition to meeting federal regulatory requirements, each state has its own laboratory certification and inspection requirements for a CLIA laboratory that must be met in order to sell diagnostic tests in the state. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | We will have to conduct expensive and time consuming clinical trials of new diagnostic tests. The full cost of conducting and completing clinical trials necessary to obtain FDA approval of IVD tests or CLIA certification of a new laboratory diagnostic test or for gaining reimbursement from health insurance companies, health maintenance organizations, Medicare, and other third party payers cannot be presently determined but could exceed our current financial resources. |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Data obtained from preclinical and clinical studies is susceptible to varying interpretations that could delay, limit or prevent regulatory agency approvals. Delays or denials of the regulatory approvals may be encountered as a result of changes in regulatory agency policy, regulations, or laws. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | A diagnostic test that is approved may be subject to restrictions on use. |
|--|--------|---------------------------------------------------------------------------|

|  | · | The FDA can withdraw approval of an FDA regulated product if problems arise |
|--|--------|-----------------------------------------------------------------------------|

|  | · | CLIA licensed laboratories can lose their licenses if problems arise during a periodic inspection. |
|--|--------|----------------------------------------------------------------------------------------------------|

|  | · | The FDA issued two draft guidance documents that set forth a proposed risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs such as those we are developing. If the FDA implements new regulatory measures: |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | We may be required to obtain pre-market clearance or approval before selling our diagnostic tests; |
|--|--------|----------------------------------------------------------------------------------------------------|

|  | · | As a result of required FDA pre-market review, our tests may not be cleared or approved on a timely basis, if at all; |
|--|--------|-----------------------------------------------------------------------------------------------------------------------|

|  | · | FDA labeling requirements may limit our claims about our diagnostic tests, which may have a negative effect on orders from physicians; |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | The regulatory approval process may involve, among other things, successfully completing additional clinical trials and making a 510(k) submission, or filing a pre-market approval application with the FDA; and, |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | If regulatory actions affect any of the reagents we obtain from suppliers and use in conducting our tests, our business could be adversely affected in the form of increased costs of testing or delays, limits or prohibitions on the purchase of reagents necessary to perform our testing. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Delays in securing clinical investigators or trial sites for our clinical trials; |
|--|--------|-----------------------------------------------------------------------------------|

|  | · | Delays in obtaining Institutional Review Board and other regulatory approvals to commence a clinical trial; |
|--|--------|-------------------------------------------------------------------------------------------------------------|

|  | · | Slower than anticipated rates of patient recruitment and enrollment, or failing to reach the targeted number of patients due to competition for patients from other trials; |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Limited or no availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third party payers for the use of our diagnostic test candidates in our clinical trials; |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Negative or inconclusive results from clinical trials; |
|--|--------|--------------------------------------------------------|

|  | · | Approval and introduction of new diagnostic or changes in standards of practice or regulatory guidance that render our clinical trial endpoints or the targeting of our proposed indications obsolete; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Inability to monitor patients adequately during or after treatment or problems with investigator or patient compliance with the trial protocols; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Inability to replicate in large controlled studies safety and efficacy data obtained from a limited number of patients in uncontrolled trials; and |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Inability or unwillingness of medical investigators to follow our clinical protocols. |
|--|--------|---------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | If data shows that the list price was greater than 130% of the payment using established methodology (a weighted median), CMS will recoup the difference from the laboratory through a payment claw back. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | Payment will be updated annually based on the weighted median of commercial payer reimbursement. |
|--|--------|--------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | The federal Anti-Kickback Statute; |
|--|--------|------------------------------------|

|  | · | The federal physician self-referral prohibition, commonly known as the Stark Law; |
|--|--------|-----------------------------------------------------------------------------------|

|  | · | The federal false claims and civil monetary penalties laws; |
|--|--------|-------------------------------------------------------------|

|  | · | The federal Physician Payment Sunshine Act requirements under the ACA; and |
|--|--------|----------------------------------------------------------------------------|

|  | · | State law equivalents of each of the federal laws enumerated above. |
|--|--------|---------------------------------------------------------------------|

|  | · | Our success will depend in part on our ability to obtain and enforce patents and maintain trade secrets in the United States and in other countries. If we are unsuccessful in obtaining and enforcing patents, our competitors could use our technology and create diagnostic tests that compete with our diagnostic tests, without paying license fees or royalties to us. |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The preparation, filing, and prosecution of patent applications can be costly and time consuming. Our limited financial resources may not permit us to pursue patent protection of all of our technology and diagnostic tests throughout the world. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Even if we are able to obtain issued patents covering our technology or diagnostic tests, we may have to incur substantial legal fees and other expenses to enforce our patent rights in order to protect our technology and diagnostic tests from infringing uses. We may not have the financial resources to finance the litigation required to preserve our patent and trade secret rights. |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | The Supreme Court decisions in Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Association for Molecular Pathology v. Myriad Genetics may adversely impact our ability to obtain patent protection for some or all of our diagnostic tests, which use certain gene markers to indicate the presence of certain cancers. The claims in the contested patents that were the subject of the Supreme Court decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc. were directed to measuring the serum level of a drug metabolite and adjusting the dosing regimen of the drug based on the metabolite level. The Supreme Court said that a patent claim that merely claimed a mathematical correlation between the blood levels of a drug metabolite and the best dosage of the drug was not patentable subject matter because it did no more than recite a correlation that occurs in nature. In Association for Molecular Pathology v. Myriad Genetics, the Supreme Court ruled that the discovery of the precise location and sequence of certain genes, mutations of which can dramatically increase the risk of breast and ovarian cancer, was not patentable. Knowledge of the gene location and sequences was used to determine the genes’ typical nucleotide sequence, which, in turn, enabled the development of medical tests useful for detecting mutations in these genes in a particular patient to assess the patient’s cancer risk. But the mere discovery of an important and useful gene did not render the genes patentable as a new composition of matter. The holdings in Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Association for Molecular Pathology v. Myriad Genetics may limit our ability to obtain patent protection on diagnostic methods that merely recite a correlation between a naturally occurring event and a diagnostic outcome associated with that event. |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The preparation and filing of patent applications, and the maintenance of patents that are issued, may require substantial time and money. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | A patent interference proceeding may be instituted with the USPTO when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validity of an issued patent. At the completion of the interference proceeding, the USPTO will determine which competing applicant is entitled to the patent, or whether an issued patent is valid. Patent interference proceedings are complex, highly contested legal proceedings, and the USPTO’s decision is subject to appeal. This means that if an interference proceeding arises with respect to any of our patent applications, we may experience significant expenses and delay in obtaining a patent, and if the outcome of the proceeding is unfavorable to us, the patent could be issued to a competitor rather than to us. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | A derivation proceeding may be instituted by the USPTO or an inventor alleging that a patent or application was derived from the work of another inventor. |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Post Grant Review under the new America Invents Act will make available opposition-like proceedings in the United States. As with the USPTO interference proceedings, Post Grant Review proceedings will be very expensive to contest and can result in significant delays in obtaining patent protection or can result in a denial of a patent application. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Oppositions to the issuance of patents may be filed under European patent law and the patent laws of certain other countries. As with USPTO interference proceedings, these foreign proceedings can be very expensive to contest and can result in significant delays in obtaining a patent or can result in a denial of a patent application. |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | We might not be able to obtain any patents beyond the bladder cancer marker patent that has been issued by the USPTO, and any patents that we do obtain might not be comprehensive enough to provide us with meaningful patent protection. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | There will always be a risk that our competitors might be able to successfully challenge the validity or enforceability of any patent issued to us. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | In addition to interference proceedings, the USPTO can reexamine issued patents at the request of a third party. Our patents may be subject to inter partes review (replacing the reexamination proceeding), a proceeding in which a third party can challenge the validity of one of our patents to have the patent invalidated. This means that patents owned or licensed by us may be subject to reexamination and may be lost if the outcome of the reexamination is unfavorable to us. |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Any amendment of our articles of incorporation or bylaws; |
|--|--------|-----------------------------------------------------------|

|  | · | Any merger or consolidation of us with another company; |
|--|--------|---------------------------------------------------------|

|  | · | Any recapitalization or reorganization of our capital stock; |
|--|--------|--------------------------------------------------------------|

----

Table of Contents

|  | · | Any sale of assets or purchase of assets; or |
|--|--------|----------------------------------------------|

|  | · | A corporate dissolution or a plan of liquidation of our business. |
|--|--------|-------------------------------------------------------------------|

|  | · | Even if we utilize different technologies than BioTime or its other subsidiaries, we could find ourselves in competition with them for research scientists, financing and other resources, licensing, manufacturing, and distribution arrangements, and for customers if we and BioTime or another BioTime subsidiary both bring diagnostic tests to market. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Because we are a subsidiary of BioTime, BioTime could prevent us from engaging in research and development programs, investments, business ventures, or agreements to develop, license, or acquire diagnostic tests or technologies that would or might compete with those owned, licensed, or under development by BioTime or any of its other subsidiaries. |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | BioTime and its other subsidiaries will engage for their own accounts in research and product development programs, investments, and business ventures, and we will not be entitled to participate or to receive an interest in those programs, investments, or business ventures. BioTime and its other subsidiaries will not be obligated to present any particular research and development, investment, or business opportunity to us, even if the opportunity would be within the scope of our research and development plans or programs, business objectives, or investment policies. These opportunities may include, for example, opportunities to acquire businesses or assets, including but not limited to patents and other intellectual property that could be used by us or by BioTime or by any of BioTime’s other subsidiaries. Our respective boards of directors will have to determine which company should pursue those opportunities, taking into account relevant facts and circumstances at the time, such as the financial and other resources of the companies available to acquire and utilize the opportunity, and the best “fit” between the opportunity and the business and research and development programs of the companies. However, since BioTime will have the ultimate power to elect the members of our Board of Directors, BioTime may have the ultimate say in decision making with respect to the allocation of opportunities. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | · | If we enter into any patent or technology license or sublicense, or any other agreement with BioTime or with another BioTime subsidiary, the BioTime companies that are parties to the agreement may have a conflict of interest in determining how and when they should enforce their rights under the agreement if the other BioTime company that is a party were to default or otherwise fail to perform any of its obligations under the agreement. |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | One of our significant assets is 619,706 BioTime common shares that we acquired from BioTime in exchange for shares of our common stock. We may sell the BioTime shares from time to time, or pledge the shares as collateral for loans, to raise capital to finance our operations. Because a sale of those shares could have a depressing effect on the market value of BioTime common shares, BioTime will have a continuing interest in the number of shares we sell, the prices at which we sell the shares, and the time and manner in which the shares are sold. Further, we may need or find it desirable to sell BioTime common shares at the same time as BioTime, or other BioTime subsidiaries that hold BioTime common shares, also desire to sell some of their BioTime common shares. Concurrent sales of BioTime common shares by us, BioTime, or other BioTime subsidiaries cold have a depressing effect on the market price of the BioTime common shares, lower the price at which we and they are able to sell BioTime common shares, and result in lower net proceeds from the sales. We plan to coordinate any future sales of our BioTime common shares with BioTime and its other subsidiaries in order to provide an orderly and controlled process for raising capital through the sale of BioTime shares. This will include an agreement as to the number of shares to be sold, the time period or “market window” for selling shares, the use of a common securities broker-dealer, and a fair allocation of net sales based on average sales prices during any trading day on which we and they sell BioTime shares. |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Each conflict of interest will be resolved by our respective boards of directors in keeping with their fiduciary duties and such policies as they may implement from time to time. However, the terms and conditions of patent and technology licenses and other agreements between us and BioTime or other BioTime subsidiaries will not be negotiated on an arm’s-length basis due to BioTime’s ownership of a controlling interest in us and due to the commonality of directors serving on our respective boards of directors. |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | · | Sales or potential sales of substantial amounts of our common stock; |
|--|--------|----------------------------------------------------------------------|

|  | · | Results of preclinical testing or clinical trials of our diagnostic test candidates or those of our competitors; |
|--|--------|------------------------------------------------------------------------------------------------------------------|

|  | · | Announcements about us or about our competitors, including clinical trial results, regulatory approvals, new diagnostic test introductions and commercial results; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The cost of our development programs; |
|--|--------|---------------------------------------|

|  | · | The success of competitive diagnostic tests or technologies; |
|--|--------|--------------------------------------------------------------|

|  | · | Litigation and other developments relating to our issued patents or patent applications or other proprietary rights or those of our competitors; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Conditions in the diagnostic, pharmaceutical or biotechnology industries; |
|--|--------|---------------------------------------------------------------------------|

|  | · | Actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Variations in our financial results or those of companies that are perceived to be similar to us, including the failure of our earnings to meet analysts’ expectations; |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | General economic, industry and market conditions; and |
|--|--------|-------------------------------------------------------|

|  | · | Changes in payer coverage and or reimbursement. |
|--|--------|-------------------------------------------------|

----

Table of Contents

----

Table of Contents

| Item 1B. | Unresolved Staff Comments |
|----------|---------------------------|

| Item 2. | Properties |
|---------|------------|

| Item 3. | Legal Proceedings |
|---------|-------------------|

| Item 4. | Mine Safety Disclosures |
|---------|-------------------------|

----

Table of Contents

| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities |
|---------|---------------------------------------------------------------------------------------------------------------------|

| Plan Category                                        | Number of Sharestobe Issued uponExercise ofOutstandingOptions, Warrants,and Rights |   | Weighted AverageExercise Price ofthe OutstandingOptions, Warrants,and Rights |   | Number of SharesRemaining Availablefor Future Issuanceunder EquityCompensation Plans |   |
|------------------------------------------------------|------------------------------------------------------------------------------------|--------|------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------|--------|
| OncoCyte Stock Option Plans Approved by Shareholders |                                                                               |   | 2,240                                                                        |   |                                                                                 | $      | 2.03 |   |   |   | 1,757 |   |

----

Table of Contents

| Item 6. | Selected Financial Data (in thousands, except per share data) |
|---------|---------------------------------------------------------------|

|                                                   |   | Year Ended December 31, |   |
|--------------------------------------------------------|--------|-------------------------|--------|
|                                                        |   |  2015              |   |   | 2014 |   |   | 2013 |   |
| OPERATING EXPENSES                                     |   |                    |   |   |   |   |   |   |   |
| Research and development                               |   | $                       | 4,527  |   |   | $ | 3,962 |   |   | $ | 2,943 |   |
| General and administrative                             |   |                    | 4,191  |   |   |   | 1,011 |   |   |   | 552 |   |
| Total operating expenses                               |   |                    | 8,718  |   |   |   | 4,973 |   |   |   | 3,495 |   |
|                                                   |   |                    |   |   |   |   |   |   |   |   |   |   |
| Loss from operations                                   |   |                    | (8,718 | ) |   |   | (4,973 | ) |   |   | (3,495 | ) |
|                                                   |   |                    |   |   |   |   |   |   |   |   |   |   |
| OTHER EXPENSES, NET                                    |   |                    |   |   |   |   |   |   |   |   |   |   |
| Interest expense, net                                  |   |                    | (19    | ) |   |   | (2 | ) |   |   | - |   |
| Other income (expense), net                            |   |                    | 2      |   |   |   | (11 | ) |   |   | - |   |
| Total other expense, net                               |   |                    | (17    | ) |   |   | (13 | ) |   |   | - |   |
|                                                   |   |                    |   |   |   |   |   |   |   |   |   |   |
| NET LOSS                                               |   | $                       | (8,735 | ) |   | $ | (4,986 | ) |   | $ | (3,495 | ) |
|                                                   |   |                    |   |   |   |   |   |   |   |   |   |   |
| Basic and diluted net loss per share                   |   | $                       | (0.42  | ) |   | $ | (0.27 | ) |   | $ | (0.19 | ) |
|                                                   |   |                    |   |   |   |   |   |   |   |   |   |   |
| Weighted average shares outstanding: basic and diluted |   |                    | 21,009 |   |   |   | 18,200 |   |   |   | 18,200 |   |
|                                                                |   | December 31,  |   |
|---------------------------------------------------------------------|--------|--------------------|--------|
|                                                                |   | 2015          |   | 2014  |   |
| Balance Sheet Data (in thousands):                                  |   |               |   |   |   |   |   |
| Cash and cash equivalents                                           |   | $                  | 7,996  |   |   | $ | 257 |   |   |
| BioTime shares held as available-for-sale securities, at fair value |   |               | 2,541  |   |   |   | 3,280 |   |   |
| Intangible assets, net                                              |   |               | 1,230  |   |   |   | 1,472 |   |   |
| Total assets                                                        |   |               | 12,731 |   |   |   | 5,241 |   |   |
| Total liabilities                                                   |   |               | 2,314  |   |   |   | 6,315 |   |   |
| Total stockholders’ equity (deficit)                          |   | $                  | 10,417 |   |   | $ | (1,074 | ) |   |

----

Table of Contents

| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|---------|---------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                |   | Years EndedDecember 31,  |   | $     |   | %   |   |
|-------------------------------------|--------|-------------------------------|--------|------------|--------|----------|--------|
|                                |   | 2015                     |   | 2014  |   | Increase |   | Increase |   |
| Research and development expenses   |   | $                             | 4,527  |       |   | $        | 3,962  |   |   | $ | +565 |   |   | $ | +14.3 | % |   |
| General and administrative expenses |   | $                             | 4,191  |       |   | $        | 1,011  |   |   | $ | +3,180 |   |   | $ | +314.5 | % |   |

|                                   |   | Amount(1) |   | Percent  |   |
|----------------------------------------|--------|-----------|--------|---------------|--------|
| Program                                |   | 2015      |   | 2014          |   | 2015 |   | 2014 |   |
|                                   |   |      |   |          |   |   |   |   |   |   |   |   |   |
| General                                |   | $         | 1,719  |          |   | $ | 1,621 |   |   |   | 38.0 | % |   |   | 40.9 | % |   |
| Bladder Cancer Confirmatory Diagnostic |   | $         | 895    |          |   | $ | 1,143 |   |   |   | 19.8 | % |   |   | 28.9 | % |   |
| Breast Cancer Confirmatory Diagnostic  |   | $         | 1,105  |          |   | $ | 1,057 |   |   |   | 24.4 | % |   |   | 26.7 | % |   |
| Lung Cancer Confirmatory Diagnostic    |   | $         | 763    |          |   | $ | 76 |   |   |   | 16.8 | % |   |   | 1.9 | % |   |
| COLX                                   |   | $         | 45     |          |   | $ | 65 |   |   |   | 1.0 | % |   |   | 1.6 | % |   |
| Total                                  |   | $         | 4,527  |          |   | $ | 3,962 |   |   |   | 100 | % |   |   | 100 | % |   |

----

|  | (1) | Amount also includes certain general research and development expenses, such as laboratory supplies, laboratory expenses, rent allocated, and insurance allocated to research and development expenses, incurred directly by BioTime on behalf of OncoCyte and allocated to OncoCyte under the Shared Facilities Agreement. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                                |   | Year EndedDecember 31, |   |       |   |             |   |             |   |
|-------------------------------------|--------|------------------------|--------|------------|--------|------------------|--------|------------------|--------|
|                                |   | 2014                   |   | 2013  |   | $ Increase  |   | % Increase  |   |
| Research and development expenses   |   | $                      | 3,962  |       |   | $                | 2,943  |             |   | $ | +1,019 |   |   |   | +35 | % |   |
| General and administrative expenses |   | $                      | 1,011  |       |   | $                | 552    |             |   | $ | +459 |   |   |   | +83 | % |   |
|                                   |   | Amount(1) |   | Percent |   |
|----------------------------------------|--------|-----------|--------|---------|--------|
| Program                                |   | 2014      |   | 2013    |   | 2014 |   | 2013 |   |
|                                   |   |      |   |    |   |   |   |   |   |   |   |   |   |
| General                                |   | $         | 1,621  |    |   | $ | 2,852 |   |   |   | 40.9 | % |   |   | 96.9 | % |   |
| Bladder Cancer Confirmatory Diagnostic |   | $         | 1,143  |    |   | $ | 27 |   |   |   | 28.9 | % |   |   | 0.9 | % |   |
| Breast Cancer Confirmatory Diagnostic  |   | $         | 1,057  |    |   | $ | 49 |   |   |   | 26.7 | % |   |   | 1.7 | % |   |
| Lung Cancer Confirmatory Diagnostic    |   | $         | 76     |    |   | $ | - |   |   |   | 1.9 | % |   |   | - | % |   |
| COLX                                   |   | $         | 65     |    |   | $ | 15 |   |   |   | 1.6 | % |   |   | 0.5 | % |   |
| Total                                  |   | $         | 3,962  |    |   | $ | 2,943 |   |   |   | 100 | % |   |   | 100 | % |   |

----

|   | (1) | Amount also includes certain general research and development expenses, such as laboratory supplies, laboratory expenses, rent allocated, and insurance allocated to research and development expenses, incurred directly by BioTime on behalf of OncoCyte and allocated to OncoCyte under the Shared Facilities Agreement. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| Item 7A. | Quantitative and Qualitative Disclosures about Market Risk |
|----------|------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Item 8. | Financial Statements and Supplementary Data |
|---------|---------------------------------------------|

|                                                                                                                                              |   | December 31, |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|---------|
|                                                                                                                                              |   | 2015    |    | 2014 |   |
| ASSETS                                                                                                                                            |   |         |    |   |   |   |   |
| CURRENT ASSETS                                                                                                                                    |   |         |    |   |   |   |   |
| Cash and cash equivalents                                                                                                                         |   | $            | 7,996   |   |   | $ | 257 |   |   |
| BioTime shares held as available-for-sale securities, at fair value                                                                               |   |         | 2,541   |   |   |   | 3,280 |   |   |
| Prepaid expenses and other current assets                                                                                                         |   |         | 388     |   |   |   | 114 |   |   |
| Total current assets                                                                                                                              |   |         | 10,925  |   |   |   | 3,651 |   |   |
|                                                                                                                                              |   |         |    |   |   |   |   |   |   |
| NONCURRENT ASSETS                                                                                                                                 |   |         |    |   |   |   |   |   |   |
| Intangible assets, net                                                                                                                            |   |         | 1,230   |   |   |   | 1,472 |   |   |
| Equipment and furniture, net                                                                                                                      |   |         | 576     |   |   |   | 118 |   |   |
| TOTAL ASSETS                                                                                                                                      |   | $            | 12,731  |   |   | $ | 5,241 |   |   |
|                                                                                                                                              |   |         |    |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                                                                                              |   |         |    |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                                                                                               |   |         |    |   |   |   |   |   |   |
| Amount due to parent, BioTime                                                                                                                     |   | $            | 807     |   |   | $ | 5,735 |   |   |
| Amount due to affiliates                                                                                                                          |   |         | 40      |   |   |   | 154 |   |   |
| Accounts payable                                                                                                                                  |   |         | 285     |   |   |   | 144 |   |   |
| Accrued expenses and other current liabilities                                                                                                    |   |         | 1,182   |   |   |   | 282 |   |   |
| Total current liabilities                                                                                                                         |   |         | 2,314   |   |   |   | 6,315 |   |   |
|                                                                                                                                              |   |         |    |   |   |   |   |   |   |
| TOTAL LIABILITIES                                                                                                                                 |   |         | 2,314   |   |   |   | 6,315 |   |   |
|                                                                                                                                              |   |         |    |   |   |   |   |   |   |
| Commitments and contingencies (see Note 9)                                                                                                        |   |         |    |   |   |   |   |   |   |
|                                                                                                                                              |   |         |    |   |   |   |   |   |   |
| STOCKHOLDERS’ EQUITY (DEFICIT)                                                                                                              |   |         |    |   |   |   |   |   |   |
| Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding                                                               |   |         | -       |   |   |   | - |   |   |
| Common stock, no par value, 50,000 shares authorized; 25,391 and 18,200 shares issued and outstanding at December 31, 2015 and 2014, respectively |   |         | 34,901  |   |   |   | 15,147 |   |   |
| Accumulated other comprehensive loss on available-for-sale securities                                                                             |   |         | (350    | ) |   |   | (822 | ) |   |
| Accumulated deficit                                                                                                                               |   |         | (24,134 | ) |   |   | (15,399 | ) |   |
| Total stockholders’ equity (deficit)                                                                                                        |   |         | 10,417  |   |   |   | (1,074 | ) |   |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                                                                                        |   | $            | 12,731  |   |   | $ | 5,241 |   |   |

----

Table of Contents

|                                                   |   | Year EndedDecember 31, |   |
|--------------------------------------------------------|--------|------------------------|--------|
|                                                   |   | 2015                   |   | 2014 |   |   | 2013 |   |
|                                                   |   |                   |   |   |   |   |   |   |   |   |   |
| OPERATING EXPENSES                                     |   |                   |   |   |   |   |   |   |   |   |   |
| Research and development                               |   | $                      | 4,527  |   |   | $ | 3,962 |   |   | $ | 2,943 |   |   |
| General and administrative                             |   |                   | 4,191  |   |   |   | 1,011 |   |   |   | 552 |   |   |
| Total operating expenses                               |   |                   | 8,718  |   |   |   | 4,973 |   |   |   | 3,495 |  |   |
|                                                   |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| Loss from operations                                   |   |                   | (8,718 | ) |   |   | (4,973 | ) |   |   | (3,495 | ) |   |
|                                                   |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| OTHER EXPENSES, NET                                    |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| Interest expense, net                                  |   |                   | (19    | ) |   |   | (2 | ) |   |   | - |   |   |
| Other expenses, net                                    |   |                   | 2      |   |   |   | (11 | ) |   |   | - |   |   |
| Total other expenses, net                              |   |                   | (17    | ) |   |   | (13 | ) |   |   | - |   |   |
|                                                   |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| NET LOSS                                               |   | $                      | (8,735 | ) |   | $ | (4,986 | ) |   | $ | (3,495 | ) |   |
|                                                   |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| Basic and diluted net loss per share                   |   | $                      | (0.42  | ) |   | $ | (0.27 | ) |   | $ | (0.19 | ) |   |
|                                                   |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average shares outstanding: basic and diluted |   |                   | 21,009 |   |   |   | 18,200 |   |   |   | 18,200 |   |   |

----

Table of Contents

|                                                                           |   | Year EndedDecember 31, |   |
|--------------------------------------------------------------------------------|--------|------------------------|--------|
|                                                                           |   | 2015              |   | 2014 |   |   | 2013 |   |
|                                                                           |   |                   |   |   |   |   |   |   |   |   |   |
| NET LOSS                                                                       |   | $                      | (8,735 | ) |   | $ | (4,986 | ) |   | $ | (3,495 | ) |   |
|                                                                           |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| Other comprehensive loss, net of tax:                                          |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| Realized loss on sale of BioTime shares                                        |   |                   | 397    |   |   |   | 569 |   |   |   | - |   |   |
| Unrealized gain (loss) on BioTime shares held as available-for-sale securities |   |                   | 75     |   |   |   | (21 | ) |   |   | 592 |   |   |
|                                                                           |   |                   |   |   |   |   |   |   |   |   |   |   |   |
| COMPREHENSIVE LOSS                                                             |   | $                      | (8,263 | ) |   | $ | (4,438 | ) |   | $ | (2,903 | ) |   |

----

Table of Contents

|                                                                                                           |   | Common Stock |   | Accumulated OtherComprehensiveLoss |   | AccumulatedDeficit |   | TotalShareholders’Equity (Deficit) |   |
|----------------------------------------------------------------------------------------------------------------|--------|--------------|--------|------------------------------------|--------|--------------------|--------|------------------------------------------|--------|
| Shares                                                                                                         |   | Amount       |
| BALANCE AT JANUARY 1, 2013                                                                                     |   |         | 18,200 |                               |   | $                  | 15,072 |                                     |   | $ | (1,962 | ) |   | $ | (6,918 | ) |   | $ | 6,192 |   |   |
| Net Loss                                                                                                       |   |         | -      |                               |   |               | -      |                                     |   |   | - |   |   |   | (3,495 | ) |   |   | (3,495 | ) |   |
| Unrealized gain on BioTime shares held as available-for-sale securities                                        |   |         | -      |                               |   |               | -      |                                     |   |   | 592 |   |   |   | - |   |   |   | 592 |   |   |
| Stock-based compensation                                                                                       |   |         | -      |                               |   |               | 326    |                                     |   |   | - |   |   |   | - |   |   |   | 326 |   |   |
| BALANCE AT DECEMBER 31, 2013                                                                              |   |         | 18,200 |                               |   | $                  | 15,398 |                                     |   | $ | (1,370 | ) |   | $ | (10,413 | ) |   | $ | 3,615 |   |   |
| Net loss                                                                                                       |   |         | -      |                               |   |               | -      |                                     |   |   | - |   |   |   | (4,986 | ) |   |   | (4,986 | ) |   |
| Unrealized gain on BioTime shares held as available-for-sale securities                                        |   |         | -      |                               |   |               | -      |                                     |   |   | (21 | ) |   |   | - |   |   |   | (21 | ) |   |
| Stock-based compensation                                                                                       |   |         | -      |                               |   |               | 318    |                                     |   |   | - |   |   |   | - |   |   |   | 318 |   |   |
| Transfer of realized loss into equity from sale of BioTime shares                                              |   |         | -      |                               |   |               | (569   | )                                        |   |   | 569 |   |   |   | - |   |   |   | - |   |   |
| BALANCE AT DECEMBER 31, 2014                                                                                   |   |         | 18,200 |                               |   |               | 15,147 |                                     |   |   | (822 | ) |   |   | (15,399 | ) |   |   | (1,074 | ) |   |
| Net loss                                                                                                       |   |         | -      |                               |   |               | -      |                                     |   |   | - |   |   |   | (8,735 | ) |   |   | (8,735 | ) |   |
| Unrealized gain on BioTime shares held as available-for-sale securities                                        |   |         | -      |                               |   |               | -      |                                     |   |   | 75 |   |   |   | - |   |   |   | 75 |   |   |
| Stock-based compensation                                                                                       |   |         | -      |                               |   |               | 1,815  |                                     |   |   | - |   |   |   | - |   |   |   | 1,815 |   |   |
| Common stock issued to BioTime for extinguishment of debt                                                      |   |         | 1,500  |                               |   |               | 3,300  |                                     |   |   | - |   |   |   | - |   |   |   | 3,300 |   |   |
| Common stock issued to investors for cash                                                                      |   |         | 1,500  |                               |   |               | 3,300  |                                     |   |   | - |   |   |   | - |   |   |   | 3,300 |   |   |
| Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest of $18 |   |         | 1,508  |                               |   |               | 3,318  |                                     |   |   | - |   |   |   | - |   |   |   | 3,318 |   |   |
| Common stock issued to BioTime for cash                                                                        |   |         | 2,711  |                               |   |               | 8,349  |                                     |   |   | - |   |   |   | - |   |   |   | 8,349 |   |   |
| Exercise of stock options                                                                                      |   |         | 3      |                               |   |               | 4      |                                     |   |   | - |   |   |   | - |   |   |   | 4 |   |   |
| Fair value of contingently issuable warrant                                                                    |   |         | -      |                               |   |               | 65     |                                     |   |   | - |   |   |   | - |   |   |   | 65 |   |   |
| OncoCyte common stock received as a dividend in kind from BioTime                                              |   |         | (31    | )                                  |   |               | -      |                                     |   |   | - |   |   |   | - |   |   |   | - |   |   |
| Transfer of realized loss into equity from sale of BioTime shares                                              |   |         | -      |                               |   |               | (397   | )                                        |   |   | 397 |   |   |   | - |   |   |   | - |   |   |
| BALANCE AT DECEMBER 31, 2015                                                                                   |   |         | 25,391 |                               |   | $                  | 34,901 |                                     |   | $ | (350 | ) |   | $ | (24,134 | ) |   | $ | 10,417 |   |   |

----

Table of Contents

|                                                                                            |   | Year EndedDecember 31 |   |
|-------------------------------------------------------------------------------------------------|--------|-----------------------|--------|
|                                                                                            |   | 2015                  |   | 2014 |   |   | 2013 |   |
| CASH FLOWS FROM OPERATING ACTIVITIES:                                                           |   |                  |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                        |   | $                     | (8,735 | ) |   | $ | (4,986 | ) |   | $ | (3,495 | ) |   |
| Adjustments to reconcile net loss to net cash used in operating activities:                     |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| Depreciation expense                                                                            |   |                  | 41     |   |   |   | 39 |   |   |   | 35 |   |   |
| Amortization of intangible assets                                                               |   |                  | 242    |   |   |   | 242 |   |   |   | 242 |   |   |
| Stock-based compensation                                                                        |   |                  | 1,815  |   |   |   | 318 |   |   |   | 326 |   |   |
| Contingently issuable warrant expense to investors                                              |   |                  | 65     |   |   |   | - |   |   |   | - |   |   |
| Interest expense                                                                                |   |                  | 18     |   |   |   | - |   |   |   | - |   |   |
| Changes in operating assets and liabilities:                                                    |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| Amount due to parent, BioTime                                                                   |   |                  | 1,672  |   |   |   | 2,823 |   |   |   | 2,136 |   |   |
| Amount due to affiliates                                                                        |   |                  | (115   | ) |   |   | 103 |   |   |   | 72 |   |   |
| Prepaid expenses and other current assets                                                       |   |                  | (274   | ) |   |   | 6 |   |   |   | (74 | ) |   |
| Accounts payable and accrued liabilities                                                        |   |                  | 1,042  |   |   |   | 291 |   |   |   | 48 |   |   |
| Net cash used in operating activities                                                           |   |                  | (4,229 | ) |   |   | (1,164 | ) |   |   | (710 | ) |   |
|                                                                                            |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:                                                           |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| Purchase of equipment                                                                           |   |                  | (500   | ) |   |   | (9 | ) |   |   | (25 | ) |   |
| Proceeds from sale of BioTime shares                                                            |   |                  | 815    |   |   |   | 1,329 |   |   |   | - |   |   |
| Net cash provided by (used in) investing activities                                             |   |                  | 315    |   |   |   | 1,320 |   |   |   | (25 | ) |   |
|                                                                                            |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:                                                           |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| Proceeds from exercise of options                                                               |   |                  | 4      |   |   |   | - |   |   |   | - |   |   |
| Proceeds from sale of common shares                                                             |   |                  | 11,649 |   |   |   | - |   |   |   | - |   |   |
| Net cash provided by financing activities                                                       |   |                  | 11,653 |   |   |   | - |   |   |   | - |   |   |
|                                                                                            |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                       |   |                  | 7,739  |   |   |   | 156 |   |   |   | (735 | ) |   |
| CASH AND CASH EQUIVALENTS:                                                                      |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| At beginning of the period                                                                      |   |                  | 257    |   |   |   | 101 |   |   |   | 836 |   |   |
| At end of the period                                                                            |   | $                     | 7,996  |   |   | $ | 257 |   |   | $ | 101 |   |   |
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES                             |   |                  |   |   |   |   |   |   |   |   |   |   |   |
| Common stock issued to BioTime for extinguishment of debt                                  |   | $                     | 3,300  |   |   | $ | - |   |   | $ | - |   |   |
| Common stock issued to BioTime upon conversion of convertible note payable and accrued interest |   |                  | 3,318  |   |   |   | - |   |   |   | - |   |   |
| Realized loss on sale of BioTime shares                                                         |   |                  | 397    |   |   |   | 569 |   |   |   | - |   |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | · | Level 1 – Quoted prices in active markets for identical assets and liabilities. |
|--|--------|---------------------------------------------------------------------------------------|

|  | · | Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                                                 |   | 2015   |   | 2014   |   | 2013   |   |
|----------------------------------------------------------------------|--------|--------|--------|--------|--------|--------|--------|
| Net loss                                                             |   | $      | (8,735 | )      |   | $      | (4,986 | ) |   | $ | (3,495 | ) |   |
| Weighted average common shares outstanding – basic and diluted |   |   | 21,009 |   |   |   | 18,200 |   |   |   | 18,200 | ) |   |
| Net loss per common share – basic and diluted                  |   | $      | (0.42  | )      |   | $      | (0.27  | ) |   | $ | (0.19 | ) |   |
|                                  |   | 2015   |   | 2014   |   |  2013  |   |
|---------------------------------------|--------|--------|--------|--------|--------|------------------|--------|
| Stock options under Stock Option Plan |   |   | 2,240  |   |   |             | 1,361  |   |   |   | 1,375 |   |   |

----

Table of Contents

----

Table of Contents

|                                      |   | 2015   |   | 2014   |   |
|-------------------------------------------|--------|--------|--------|--------|--------|
| Prepaid license fees                      |   | $      | 19     |   |   | $ | 111 |   |   |
| Outside research                          |   |   | 366    |   |   |   | - |   |   |
| Other prepaid expenses and current asset  |   |   | 3      |   |   |   | 3 |   |   |
| Prepaid expenses and other current assets |   | $      | 388    |   |   | $ | 114 |   |   |
|                                           |   | 2015   |   | 2014   |   |
|------------------------------------------------|--------|--------|--------|--------|--------|
| Accrued bonuses and payroll related expenses   |   | $      | 325    |   |   | $ | 147 |   |   |
| Other accrued expenses                         |   |   | 857    |   |   |   | 135 |   |   |
| Accrued expenses and other current liabilities |   | $      | 1,182  |   |   | $ | 282 |   |   |
|                     |   | 2015   |   | 2014   |   |
|--------------------------|--------|--------|--------|--------|--------|
| Intangible assets        |   | $      | $2,419 |   |   | $ | $2,419 |   |   |
| Accumulated amortization |   |   | (1,189 | )      |   |   | (947 | ) |   |
| Intangible assets, net   |   | $      | $1,230 |   |   | $ | $1,472 |   |   |

----

Table of Contents

|                         |   | 2015   |   | 2014   |   |
|------------------------------|--------|--------|--------|--------|--------|
| Equipment and furniture      |   | $      | 750    |   |   | $ | 251 |   |   |
| Accumulated depreciation     |   |   | (174   | )      |   |   | (133 | ) |   |
| Equipment and furniture, net |   | $      | 576    |   |   | $ | 118 |   |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Options                          |   | Available forGrant |    |   | Number ofShares |   |   | WeightedAverageExercisePrice |   |
|----------------------------------|--------|--------------------|---------|--------|-----------------|--------|--------|------------------------------|--------|
| Outstanding at January 1, 2014   |   |               | 625     |   |            |   |   | 1,375                        |   |   |   | $ | 1.53 |   |   |
| Granted                          |   |               | -       |   |            |   |   | -                            |   |   |   |   | - |   |   |
| Options forfeited or cancelled   |   |               | 14      |   |            |   |   | (14)                         |   |   |   |   | 2.00 |   |   |
| Outstanding at December 31, 2014 |   |               | 639     |   |            |   |   | 1,361                        |   |   |   | $ | 1.52 |   |   |
| Increase in option pool          |   |               | 2,000   |   |            |   |   |                         |   |   |   |   |   |   |   |
| Options granted                  |   |               | (1,448) |   |                 |   |   | 1,448                        |   |   |   |   | 2.21 |   |   |
| Options exercised                |   |               | -       |   |            |   |   | (3)                          |   |   |   |   | 1.34 |   |   |
| Options forfeited or cancelled   |   |               | 566     |   |            |   |   | (566)                        |   |   |   |   | 1.59 |   |   |
| Outstanding at December 31, 2015 |   |               | 1,757   |   |            |   |   | 2,240                        |   |   |   | $ | 2.03 |   |   |
| Exercisable at December 31, 2015 |   |               |    |   |            |   | 972    |                         |   |   | $ | 1.61 |   |   |

----

Table of Contents

|                                   |   | 2015   |   | 2014   |   |  2013 |   |
|----------------------------------------|--------|--------|--------|--------|--------|------------|--------|
| Research and development               |   | $      | 456    |   |   | $          | 177    |   |   | $ | 183 |   |   |
| General and administrative             |   |   | 1,359  |   |   |       | 141    |   |   |   | 143 |   |   |
| Total stock-based compensation expense |   | $      | 1,815  |   |   | $          | 318    |   |   | $ | 326 |   |   |
|                     |   | 2015   |   | 2014(1) |   |  2013 |   |
|--------------------------|--------|--------|--------|---------|--------|------------|--------|
| Expected life (in years) |   |   | 6.83   |    |   |       | -      |   |   |   | 4.13 |   |   |
| Risk-free interest rates |   |   | 1.87   | %       |   |       | -      | % |   |   | 1.28 | % |   |
| Volatility               |   |   | 74.15  | %       |   |       | -      | % |   |   | 70.68 | % |   |
| Dividend yield           |   |   | -      | %       |   |       | -      | % |   |   | - | % |   |

----

|  | (1) | No stock options were granted in 2014. |
|--|-----|----------------------------------------|

----

Table of Contents

|                                       |   | December 31, 2014 |   |
|--------------------------------------------|--------|-------------------|--------|
|                                       |   | As reported       |   | Adjustment due to retrospective adoption of ASU 2015-17 |   | As adjusted |   |
| Total  assets                         |   | $                 | 6,356  |   |   | $ | (1,115 | ) |   | $ | 5,241 |   |   |
| Total liabilities                          |   |              | 7,430  |   |   |   | (1,115 | ) |   |   | 6,315 |   |   |
| Total liabilities and stockholders' equity |   |              | 6,356  |   |   |   | (1,115 | ) |   |   | 5,241 |   |   |
| Working capital deficit                    |   |              | (3,779 | ) |   |   | 1,115 |   |   |   | (2,664 | ) |   |

|                                          |   | 2015   |   | 2014   |   |
|-----------------------------------------------|--------|--------|--------|--------|--------|
| Deferred liabilities:                         |   |   |   |   |   |   |   |
| Available-for-sale securities                 |   | $      | (864   | )      |   | $ | (1,115 | ) |   |
| Total deferred tax liabilities                |   | $      | (864   | )      |   | $ | (1,115 | ) |   |
|                                          |   |   |   |   |   |   |   |   |   |
| Deferred tax assets:                          |   |   |   |   |   |   |   |   |   |
| Net operating loss carryforwards              |   | $      | 8,139  |   |   | $ | 4,879 |   |   |
| Research and development credit carryforwards |   |   | 1,362  |   |   |   | 1,030 |   |   |
| Patents and fixed assets                      |   |   | 136    |   |   |   | 141 |   |   |
| Stock-based compensation                      |   |   | 98     |   |   |   | 24 |   |   |
| Valuation Allowance                           |   |   | (8,871 | )      |   |   | (4,959 | ) |   |
| Total deferred tax assets                     |   | $      | 864    |   |   | $ | 1,115 |   |   |
| Net deferred tax asset (liability)            |   | $      | -      |   |   | $ | - |   |   |

|                                           |   | 2015   |   | 2014 |   | 2013   |   |
|------------------------------------------------|--------|--------|--------|------|--------|--------|--------|
| Computed tax benefit at federal statutory rate |   |   | 34     | %    |   |   | 34     | % |   |   | 34 | % |   |
| Permanent differences                          |   |   | (9     | %)   |   |   | (2     | %) |   |   | (3 | %) |   |
| State tax benefit                              |   |   | 15     | %    |   |   | -      |   |   |   | - |   |   |
| Research and development credits               |   |   | 2      | %    |   |   | 2      | % |   |   | 3 | % |   |
| Other                                          |   |   | 3      | %    |   |   | -      |   |   |   | - |   |   |
| Change in valuation allowance                  |   |   | (45    | %)   |   |   | (34    | %) |   |   | (34 | %) |   |
|                                           |   |   | 0      | %    |   |   | 0      | % |   |   | 0 | % |   |

----

Table of Contents

----

Table of Contents

| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure |
|---------|--------------------------------------------------------------------------------------|

----

Table of Contents

| Item 9A. | Controls and Procedures |
|----------|-------------------------|

|  | · | Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Item 9B. | Other Information |
|----------|-------------------|

----

Table of Contents

----

Table of Contents

| Item 15. | Exhibits, Financial Statement Schedules |
|----------|-----------------------------------------|

| (a-1) | Financial Statements. |
|-------|-----------------------|

| (a-2) | Financial Statement Schedules |
|-------|-------------------------------|

| (a-3) | Exhibits. |
|-------|-----------|

| Exhibit Numbers |   | Exhibit Description                                                                                   |
|-----------------|--------|-------------------------------------------------------------------------------------------------------|
| 3.1             |   | Articles of Incorporation, as amended (1)                                                             |
|            |   |                                                                                                  |
| 3.2             |   | By-Laws, as amended (1)                                                                               |
|            |   |                                                                                                  |
| 4.1             |   | Specimen of Common Stock Certificate (2)                                                              |
|            |   |                                                                                                  |
| 10.1            |   | Shared Facilities Agreement, dated October 8, 2009 between OncoCyte Corporation and BioTime, Inc. (1) |
|            |   |                                                                                                  |
| 10.2            |   | Stock Option Plan, as amended (1)                                                                     |
|            |   |                                                                                                  |
| 10.3            |   | Form of Employee Incentive Stock Option Agreement (1)                                                 |
|            |   |                                                                                                  |
| 10.4            |   | Form of Director/Consultant Option Agreement (1)                                                      |
|            |   |                                                                                                  |
| 10.5            |   | Employment Agreement, dated April 1, 2011, between OncoCyte Corporation and Karen Chapman (1)         |
|            |   |                                                                                                  |
| 10.6            |   | Employment Agreement, dated June 15, 2015, between OncoCyte Corporation and William Annett (1)        |
|            |   |                                                                                                  |
| 10.7            |   | Employment Agreement, dated August 1, 2015, between OncoCyte Corporation and Kristine Mechem (1)      |
|            |   |                                                                                                  |
| 10.8            |   | Registration Rights Agreement dated October 15, 2009 (1)                                              |
|            |   |                                                                                                  |
| 10.9            |   | Amendment of Registration Rights Agreement, dated August 23, 2011 (1)                                 |
|            |   |                                                                                                  |
| 10.10           |   | Second Amendment of Registration Rights Agreement, dated May 8, 2015 (1)                              |

----

Table of Contents

| 10.11  |   | Subscription Agreement, dated May 8, 2015, between OncoCyte Corporation and George Karfunkel (1)                                                                                                                                                             |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                         |
| 10.12  |   | Subscription Agreement, dated May 8, 2015, between OncoCyte Corporation and Bernard Karfunkel (1)                                                                                                                                                            |
|   |   |                                                                                                                                                                                                                                                         |
| 10.13  |   | Convertible Promissory Note, dated May 8, 2015, payable to BioTime, Inc. (1)                                                                                                                                                                                 |
|   |   |                                                                                                                                                                                                                                                         |
| 10.14  |   | Agreement, dated June 26, 2015, between OncoCyte Corporation and George Karfunkel and Bernard Karfunkel (1)                                                                                                                                                  |
|   |   |                                                                                                                                                                                                                                                         |
| 10.15  |   | Sponsored Research Agreement, dated September 18, 2013, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (1)                       |
|   |   |                                                                                                                                                                                                                                                         |
| 10.16  |   | First Amendment to the Sponsored Research Agreement, dated August 6, 2015, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (1)    |
|   |   |                                                                                                                                                                                                                                                         |
| 10.17  |   | Subscription Agreement, dated September 29, 2015, between OncoCyte Corporation and BioTime, Inc. (1)                                                                                                                                                         |
|   |   |                                                                                                                                                                                                                                                         |
| 10.18  |   | Second Amendment to the Sponsored Research Agreement, dated October 18, 2015, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (1) |
|   |   |                                                                                                                                                                                                                                                         |
| 10.19  |   | Third Amendment to Registration Rights Agreement, dated November 16, 2015 (2)                                                                                                                                                                                |
|   |   |                                                                                                                                                                                                                                                         |
| 10.20  |   | Third Amendment to the Sponsored Research Agreement, dated December 1, 2015, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (2)                                                                                                |
|   |   |                                                                                                                                                                                                                                                         |
| 10.21  |   | License Agreement, dated January 22, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment)*                                       |
|   |   |                                                                                                                                                                                                                                                         |
| 10.22  |   | First Amendment to License Agreement, dated January 25, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology*                                                                                                                  |
|   |   |                                                                                                                                                                                                                                                         |
| 23.1   |   | Consent of OUM & Co. LLP*                                                                                                                                                                                                                                |
|   |   |                                                                                                                                                                                                                                                         |
| 31     |   | Rule 13a-14(a)/15d-14(a) Certification *                                                                                                                                                                                                                     |
|   |   |                                                                                                                                                                                                                                                         |
| 32     |   | Section 1350 Certification *                                                                                                                                                                                                                                 |

| (1) | Incorporated by reference to OncoCyte Corporation’s Form 10 12(b) filed on November 23, 2015. |
|-----|-----------------------------------------------------------------------------------------------------|

| (2) | Incorporated by reference to OncoCyte Corporation’s Form 10 12(b) A-1 filed on December 29, 2015. |
|-----|---------------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | ONCOCYTE CORPORATION |                                  |
|--------|----------------------|---------------------------------------|
|   |                 |                                  |
|   | By:                  | /s/William Annett                     |   |
|   |                 | William Annett                        |   |
|   |                 | President and Chief Executive Officer |   |

| Signature              |   | Title                                     |   | Date           |
|------------------------|--------|-------------------------------------------|--------|----------------|
|                   |   |                                      |   |           |
| /s/William Annett      |   | President and Chief Executive Officer and |   | March 30, 2016 |
| WILLIAM ANNETT         |   | Director (Principal Executive Officer)    |   |           |
|                   |   |                                      |   |           |
| /s/Russell L. Skibsted |   | Chief Financial Officer (Principal        |   | March 30, 2016 |
| RUSSELL L. SKIBSTED    |   | Financial and Accounting Officer)         |   |           |
|                   |   |                                      |   |           |
| /s/Andrew Arno         |   | Director                                  |   | March 30, 2016 |
| ANDREW ARNO            |   |                                      |   |           |
|                   |   |                                      |   |           |
| /s/ Cavan Redmond      |   | Director                                  |   | March 30, 2016 |
| CAVAN REDMOND          |   |                                      |   |           |
|                   |   |                                      |   |           |
| /s/Alfred D. Kingsley  |   | Director                                  |   | March 30, 2016 |
| ALFRED D. KINGSLEY     |   |                                      |   |           |
|                   |   |                                      |   |           |
| /s/Andrew Last         |   | Director                                  |   | March 30, 2016 |
| ANDREW LAST            |   |                                      |   |           |
|                   |   |                                      |   |           |
| /s/Aditya Mohanty      |   | Director                                  |   | March 30, 2016 |
| ADITYA MOHANTY         |   |                                      |   |           |
|                   |   |                                      |   |           |
| /s/Michael D. West     |   | Director                                  |   | March 30, 2016 |
| MICHAEL D. WEST        |   |                                      |   |           |

----

Table of Contents

| Exhibit Numbers |   | Exhibit Description                                                                                                                                                                                                                                          |
|-----------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1             |   | Articles of Incorporation, as amended (1)                                                                                                                                                                                                                    |
|            |   |                                                                                                                                                                                                                                                         |
| 3.2             |   | By-Laws, as amended (1)                                                                                                                                                                                                                                      |
|            |   |                                                                                                                                                                                                                                                         |
| 4.1             |   | Specimen of Common Stock Certificate (2)                                                                                                                                                                                                                     |
|            |   |                                                                                                                                                                                                                                                         |
| 10.1            |   | Shared Facilities Agreement, dated October 8, 2009 between OncoCyte Corporation and BioTime, Inc. (1)                                                                                                                                                        |
|            |   |                                                                                                                                                                                                                                                         |
| 10.2            |   | Stock Option Plan, as amended (1)                                                                                                                                                                                                                            |
|            |   |                                                                                                                                                                                                                                                         |
| 10.3            |   | Form of Employee Incentive Stock Option Agreement (1)                                                                                                                                                                                                        |
|            |   |                                                                                                                                                                                                                                                         |
| 10.4            |   | Form of Director/Consultant Option Agreement (1)                                                                                                                                                                                                             |
|            |   |                                                                                                                                                                                                                                                         |
| 10.5            |   | Employment Agreement, dated April 1, 2011, between OncoCyte Corporation and Karen Chapman (1)                                                                                                                                                                |
|            |   |                                                                                                                                                                                                                                                         |
| 10.6            |   | Employment Agreement, dated June 15, 2015, between OncoCyte Corporation and William Annett (1)                                                                                                                                                               |
|            |   |                                                                                                                                                                                                                                                         |
| 10.7            |   | Employment Agreement, dated August 1, 2015, between OncoCyte Corporation and Kristine Mechem (1)                                                                                                                                                             |
|            |   |                                                                                                                                                                                                                                                         |
| 10.8            |   | Registration Rights Agreement dated October 15, 2009 (1)                                                                                                                                                                                                     |
|            |   |                                                                                                                                                                                                                                                         |
| 10.9            |   | Amendment of Registration Rights Agreement, dated August 23, 2011 (1)                                                                                                                                                                                        |
|            |   |                                                                                                                                                                                                                                                         |
| 10.10           |   | Second Amendment of Registration Rights Agreement, dated May 8, 2015 (1)                                                                                                                                                                                     |
|            |   |                                                                                                                                                                                                                                                         |
| 10.11           |   | Subscription Agreement, dated May 8, 2015, between OncoCyte Corporation and George Karfunkel (1)                                                                                                                                                             |
|            |   |                                                                                                                                                                                                                                                         |
| 10.12           |   | Subscription Agreement, dated May 8, 2015, between OncoCyte Corporation and Bernard Karfunkel (1)                                                                                                                                                            |
|            |   |                                                                                                                                                                                                                                                         |
| 10.13           |   | Convertible Promissory Note, dated May 8, 2015, payable to BioTime, Inc. (1)                                                                                                                                                                                 |
|            |   |                                                                                                                                                                                                                                                         |
| 10.14           |   | Agreement, dated June 26, 2015, between OncoCyte Corporation and George Karfunkel and Bernard Karfunkel (1)                                                                                                                                                  |
|            |   |                                                                                                                                                                                                                                                         |
| 10.15           |   | Sponsored Research Agreement, dated September 18, 2013, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (1)                       |
|            |   |                                                                                                                                                                                                                                                         |
| 10.16           |   | First Amendment to the Sponsored Research Agreement, dated August 6, 2015, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (1)    |
|            |   |                                                                                                                                                                                                                                                         |
| 10.17           |   | Subscription Agreement, dated September 29, 2015, between OncoCyte Corporation and BioTime, Inc. (1)                                                                                                                                                         |
|            |   |                                                                                                                                                                                                                                                         |
| 10.18           |   | Second Amendment to the Sponsored Research Agreement, dated October 18, 2015, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (1) |

----

Table of Contents

| 10.19  |   | Third Amendment to Registration Rights Agreement, dated November 16, 2015 (2)                                                                                                                                          |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                   |
| 10.20  |   | Third Amendment to the Sponsored Research Agreement, dated December 1, 2015, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (2)                                                          |
|   |   |                                                                                                                                                                                                                   |
| 10.21  |   | License Agreement, dated January 22, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment)* |
|   |   |                                                                                                                                                                                                                   |
| 10.22  |   | First Amendment to License Agreement, dated January 25, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology*                                                                            |
|   |   |                                                                                                                                                                                                                   |
| 23.1   |   | Consent of OUM & Co. LLP*                                                                                                                                                                                          |
|   |   |                                                                                                                                                                                                                   |
| 31     |   | Rule 13a-14(a)/15d-14(a) Certification *                                                                                                                                                                               |
|   |   |                                                                                                                                                                                                                   |
| 32     |   | Section 1350 Certification *                                                                                                                                                                                           |

| (1) | Incorporated by reference to OncoCyte Corporation’s Form 10 12(b) filed on November 23, 2015. |
|-----|-----------------------------------------------------------------------------------------------------|

| (2) | Incorporated by reference to OncoCyte Corporation’s Form 10 12(b) A-1 filed on December 29, 2015. |
|-----|---------------------------------------------------------------------------------------------------------|

----